Beyond pyrexia, rash and photosensitivity—common dermatologic toxicities—have been analogized in other kinase inhibitor settings (e.g., EGFR inhibitors) as correlates of adequate target inhibition, though direct evidence in melanoma/triose MAPK contexts remains limited [50,51]. Here, EGFR is linked to melanoma.